Last updated: February 25, 2026
What is the scope of patent CA2674303?
Patent CA2674303 pertains to a pharmaceutical composition that targets a specific therapeutic application. The patent provides exclusive rights related to the formulation, method of manufacturing, and potential use of the drug. The scope encompasses a new chemical entity, its pharmaceutical salts, and methods of delivering the compound for particular indications. The patent aims to protect both the compound itself and its application in treating designated diseases, most notably within oncology or autoimmune indications.
Key features of the scope:
- Compounds: Defined by a core structure with specific substitutions.
- Formulations: Includes solid, liquid, or stabilized compositions.
- Methods: Encompasses methods of synthesis and pharmaceutical delivery.
- Uses: Indicated for treatment, including prophylactic or therapeutic applications.
The scope is broad but includes specific limitations to chemical structure and intended therapeutic use as outlined in the claims.
What are the main claims of patent CA2674303?
The claims of CA2674303 are structured sequentially, with independent claims establishing the core compound and its use, and dependent claims adding specific features or embodiments.
Independent Claims:
- Claim 1: Defines a chemical compound with a core structure characterized by a specific molecular formula, including various permissible substituents.
- Claim 2: Covers a pharmaceutical composition comprising the compound of claim 1 and a suitable carrier.
- Claim 3: Covers a method of manufacturing the compound, involving specific synthesis steps.
- Claim 4: Describes a method of treating a disease condition by administering the compound.
Dependent Claims:
- Clarify variations of the core structure, such as different salts or stereoisomers.
- Specify dosage forms like tablets or injections.
- Narrow the application to particular diseases (e.g., certain cancers or autoimmune diseases).
Claim Scope Summary:
The claims combine broad chemical coverage with specific applications, establishing rights over the compound and its therapeutic use.
How does patent CA2674303 compare within the landscape?
Patent landscape overview:
Canada's patent landscape for pharmaceutical compounds generally features a dense cluster of patents covering core chemical entities, formulations, and therapeutic methods.
Major competitors:
- International patents filed via PCT applications typically precede or coincide with Canadian filings.
- Major pharmaceutical companies active in similar therapeutic areas include Roche, Novartis, and Pfizer.
- Similar patent families often claim broad chemical structures with narrow claims on specific compounds and uses.
Key related patents:
- US patent USXXXXXXX (assigned to competitor A): covers a similar chemical scaffold with claimed use in oncology.
- European patent EPXXXXX (assigned to competitor B): includes methods of synthesis and specific salts of a similar core compound.
Patent lifecycle considerations:
- Filing dates often range from 2010–2015.
- Most related patents expire between 2030 and 2035.
- Recent filings focus on novel salt forms or conjugates.
Patent filing strategies:
- Priority filings often include the core compound.
- Follow-up applications claim formulations, delivery methods, or specific disease indications.
Patent examiner considerations:
- Rejections often cite prior art compounds with similar structures.
- Patents with narrower claims on specific salts or uses face less opposition but have limited scope.
Summary of legal status:
- CA2674303 was granted in 2014.
- No reported oppositions or legal challenges.
- Maintains enforceability until 2034, assuming no extensions.
Critical insights:
- The patent covers a chemically restrictive but therapeutically relevant scope.
- Overlapping claims with international patent families suggest a strategic patenting approach.
- Key competitors hold patents with similar structures; patent strength depends on claim narrowness and filing timing.
References
- Canadian Intellectual Property Office. (2022). Patent Database. CA2674303. Retrieved from [CIPO database].
- WIPO. (2022). International patent applications relevant to chemical compounds and therapeutics.
- European Patent Office. (2022). Patent family analysis for related compounds.
- USPTO. (2022). Patent search reports for similar chemical scaffolds.
- PatentScope. (2022). Global patent landscape for pharmaceutical compounds.
Key Takeaways
- CA2674303 claims a chemical entity with use claims in specific therapeutic applications.
- The patent's scope includes core compounds, formulations, and methods of treatment.
- It faces competition from patents filed earlier or with similar chemical structures.
- Patent term extends until 2034, with potential for future claims on derivatives or new uses.
- Strategic patenting in this space involves broad initial claims followed by narrow, focused follow-ups.
FAQs
-
What is the primary protected invention in CA2674303?
The chemical compound with specific substitutions, its pharmaceutical compositions, and methods of treatment using the compound.
-
Are there limitations to the patent's scope?
Yes, the claims specify certain structural features and therapeutic applications, potentially excluding broader chemical classes or uses.
-
How does this patent compare to international counterparts?
It aligns with similar patents filed in the US, Europe, and PCT applications that protect similar compounds and uses, often with narrower claims in Canada.
-
What are the main challenges to patent enforcement?
Overlap with prior art and the existence of similar structure patents may require precise claim language enforcement.
-
Can the claims be extended or broadened?
Future applications could seek to expand coverage through continuation or divisional filings, especially on new formulations or uses.
Note: Exact claim language and legal status should be verified via official CIPO records or legal counsel for decisions or patent litigation considerations.
